Get the Stockscreener App
6.04
3.67%
-0.23
After Hours:
6.04
Recursion Pharmaceuticals Inc stock is traded at $6.04, with a volume of 16.19M.
It is down -3.67% in the last 24 hours and down -12.97% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$6.27
Open:
$6.3
24h Volume:
16.19M
Relative Volume:
3.07
Market Cap:
$1.69B
Revenue:
$43.88M
Net Income/Loss:
$-328.07M
P/E Ratio:
-4.3768
EPS:
-1.38
Net Cash Flow:
$-300.33M
1W Performance:
-17.49%
1M Performance:
-12.97%
6M Performance:
-38.24%
1Y Performance:
-11.95%
1-Day Range:
$5.70
$6.37
1-Week Range:
$5.70
$7.58
52-Week Range:
$5.70
$15.74
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| RXRX | 6.04 | 1.69B | 43.88M | -328.07M | -300.33M | -1.38 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Trans-Atlantic Triumph: AI Drug Pioneers Recursion, Exscientia Combine - Genetic Engineering & Biotechnology News
Cathie Wood's ARK makes major plays in Recursion, Twist Bioscience stock - Investing.com
RecursionNo News Isn't Good News When It Comes To Vanilla Pipeline (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals’ Strategic Acquisition and Leadership Changes - TipRanks
Recursion and Exscientia, Two Leaders in the AI Drug Discovery Space, Have Officially Combined to Advance the Industrialization of Drug Discovery - Wahanariau
Recursion and Exscientia, two leaders in the AI drug - GlobeNewswire
Recursion Completes Exscientia Merger, Creates AI Drug Discovery Powerhouse with $20B+ Pipeline | RXRX Stock News - StockTitan
Recursion Pharmaceuticals stock hits 52-week low at $5.88 - Investing.com India
Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 1-Year LowHere's What Happened - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $5.88 By Investing.com - Investing.com Canada
Recursion Pharmaceuticals CEO sells $301,800 in stock - Investing.com India
Recursion Pharmaceuticals director Blake Borgeson sells $87,457 in stock - Investing.com Canada
Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% Following Insider Selling - MarketBeat
Insider Sale: Director Blake Borgeson Sells Shares of Recursion Pharmaceuticals Inc (RXRX) - GuruFocus.com
Sumitomo Mitsui Trust Group Inc. Trims Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals CFO Michael Secora sells $229,504 in stock - Investing.com
Pier 88 Investment Partners LLC Acquires 109,210 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Recursion and Exscientia Shareholders Approve the Proposed Combination - The Manila Times
Recursion & Exscientia Merger Approved: AI Drug Discovery Giants Set to Unite | RXRX Stock News - StockTitan
Recursion releases OpenPhenom-S/16 for microscopy data By Investing.com - Investing.com Australia
FMR LLC's Strategic Acquisition in Recursion Pharmaceuticals Inc - GuruFocus.com
Recursion releases OpenPhenom-S/16 for microscopy data - Investing.com
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden - GlobeNewswire
Recursion Pharmaceuticals, Inc. Announces the Release of OpenPhenom-S/16 in Google Cloud?s Model Garden - Marketscreener.com
Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Leerink Partnrs Issues Optimistic Estimate for RXRX Earnings - MarketBeat
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - Simply Wall St
Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - Yahoo Finance
ARK Investment Management LLC Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk - Simply Wall St
A Closer Look at 4 Analyst Recommendations For Recursion Pharmaceuticals - Benzinga
Recursion Pharmaceuticals' (RXRX) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates - MSN
Recursion Pharmaceuticals Reports Q3 2024 Earnings and Strategic Milestones - TipRanks
Recursion Pharmaceuticals: Q3 Earnings Snapshot - Barchart
Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results - GlobeNewswire
Recursion Pharmaceuticals Inc Cl A (RXRX-Q) QuotePress Release - The Globe and Mail
Is Recursion Pharmaceuticals a Millionaire-Maker Stock? - AOL
Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Pre - GuruFocus.com
Vanguard Group Inc's Strategic Acquisition in Recursion Pharmace - GuruFocus.com
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider - MSN
(RXRX) Technical Pivots with Risk Controls - Stock Traders Daily
Could This Near Trillion-Dollar Stock Be a Millionaire Maker? - AOL
Mirae Asset Global Investments Co. Ltd. Purchases 80,664 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - MarketBeat
Recursion Pharmaceuticals director Blake Borgeson sells $76,926 in stock - Investing.com India
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):